Literature DB >> 11044072

Efficacy and safety studies of a recombinant chimeric respiratory syncytial virus FG glycoprotein vaccine in cotton rats.

G A Prince1, C Capiau, M Deschamps, L Fabry, N Garçon, D Gheysen, J P Prieels, G Thiry, O Van Opstal, D D Porter.   

Abstract

Several formulations of a recombinant chimeric respiratory syncytial virus (RSV) vaccine consisting of the extramembrane domains of the F and G glycoproteins (FG) were tested in cotton rats to evaluate efficacy and safety. The FG vaccine was highly immunogenic, providing nearly complete resistance to pulmonary infection at doses as low as 25 ng in spite of inducing relatively low levels of serum neutralizing antibody at low vaccine doses. Upon RSV challenge animals primed with FG vaccine showed quite mild alveolitis and interstitial pneumonitis, which were eliminated by the addition of monophosphoryl lipid A to the formulation.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 11044072      PMCID： PMC110902          DOI： 10.1128/jvi.74.22.10287-10292.2000

Source DB:  PubMed          Journal:  J Virol        ISSN： 0022-538X            Impact factor:   5.103


  36 in total

1.  The immunogenicity of subunit vaccines for respiratory syncytial virus after co-formulation with aluminum hydroxide adjuvant and recombinant interleukin-12.

Authors:  G E Hancock; J D Smith; K M Heers
Journal:  Viral Immunol       Date:  2000       Impact factor: 2.257

2.  Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine.

Authors:  H W Kim; J G Canchola; C D Brandt; G Pyles; R M Chanock; K Jensen; R H Parrott
Journal:  Am J Epidemiol       Date:  1969-04       Impact factor: 4.897

3.  An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine.

Authors:  A Z Kapikian; R H Mitchell; R M Chanock; R A Shvedoff; C E Stewart
Journal:  Am J Epidemiol       Date:  1969-04       Impact factor: 4.897

4.  Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population.

Authors:  J Chin; R L Magoffin; L A Shearer; J H Schieble; E H Lennette
Journal:  Am J Epidemiol       Date:  1969-04       Impact factor: 4.897

5.  Pulmonary lesions in primary respiratory syncytial virus infection, reinfection, and vaccine-enhanced disease in the cotton rat (Sigmodon hispidus).

Authors:  G A Prince; J P Prieels; M Slaoui; D D Porter
Journal:  Lab Invest       Date:  1999-11       Impact factor: 5.662

6.  Influence of administration dose and route on the immunogenicity and protective efficacy of BBG2Na, a recombinant respiratory syncytial virus subunit vaccine candidate.

Authors:  L Goetsch; H Plotnicky-Gilquin; T Champion; A Beck; N Corvaïa; S Stâhl; J Y Bonnefoy; T N Nguyen; U F Power
Journal:  Vaccine       Date:  2000-06-01       Impact factor: 3.641

7.  Partial protection to respiratory syncytial virus (RSV) elicited in mice by intranasal immunization using live staphylococci with surface-displayed RSV-peptides.

Authors:  F Cano; H Plotnicky-Gilquin; T N Nguyen; S Liljeqvist; P Samuelson; J Bonnefoy; S Stâhl; A Robert
Journal:  Vaccine       Date:  2000-06-01       Impact factor: 3.641

8.  Effective mucosal immunization against respiratory syncytial virus using purified F protein and a genetically detoxified cholera holotoxin, CT-E29H.

Authors:  P W Tebbey; C A Scheuer; J A Peek; D Zhu; N A LaPierre; B A Green; E D Phillips; A R Ibraghimov; J H Eldridge; G E Hancock
Journal:  Vaccine       Date:  2000-06-01       Impact factor: 3.641

9.  Absence of lung immunopathology following respiratory syncytial virus (RSV) challenge in mice immunized with a recombinant RSV G protein fragment.

Authors:  H Plotnicky-Gilquin; T Huss; J P Aubry; J F Haeuw; A Beck; J Y Bonnefoy; T N Nguyen; U F Power
Journal:  Virology       Date:  1999-05-25       Impact factor: 3.616

10.  Respiratory virus immunization. I. A field trial of two inactivated respiratory virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine.

Authors:  V A Fulginiti; J J Eller; O F Sieber; J W Joyner; M Minamitani; G Meiklejohn
Journal:  Am J Epidemiol       Date:  1969-04       Impact factor: 4.897
View more
  9 in total

Review 1.  New insights for development of a safe and protective RSV vaccine.

Authors:  Jorge C G Blanco; Marina S Boukhvalova; Kari Ann Shirey; Gregory A Prince; Stefanie N Vogel
Journal:  Hum Vaccin       Date:  2010-06-01

2.  Pathogenesis of human metapneumovirus lung infection in BALB/c mice and cotton rats.

Authors:  Marie-Eve Hamelin; Kevin Yim; Katie H Kuhn; Rose P Cragin; Marina Boukhvalova; Jorge C G Blanco; Gregory A Prince; Guy Boivin
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

Review 3.  Respiratory syncytial virus vaccine development.

Authors:  Julia L Hurwitz
Journal:  Expert Rev Vaccines       Date:  2011-10       Impact factor: 5.217

4.  Development of an intradermal DNA vaccine delivery strategy to achieve single-dose immunity against respiratory syncytial virus.

Authors:  Trevor R F Smith; Katherine Schultheis; Matthew P Morrow; Kimberly A Kraynyak; Jay R McCoy; Kevin C Yim; Karuppiah Muthumani; Laurent Humeau; David B Weiner; Niranjan Y Sardesai; Kate E Broderick
Journal:  Vaccine       Date:  2017-04-14       Impact factor: 3.641

5.  Dual role of interleukin-10 in the regulation of respiratory syncitial virus (RSV)-induced lung inflammation.

Authors:  L Sun; T T Cornell; A LeVine; A A Berlin; V Hinkovska-Galcheva; A J Fleszar; N W Lukacs; T P Shanley
Journal:  Clin Exp Immunol       Date:  2013-05       Impact factor: 4.330

6.  Immunoprotective activity and safety of a respiratory syncytial virus vaccine: mucosal delivery of fusion glycoprotein with a CpG oligodeoxynucleotide adjuvant.

Authors:  Gregory A Prince; James J Mond; David D Porter; Kevin C Yim; Steve J Lan; Dennis M Klinman
Journal:  J Virol       Date:  2003-12       Impact factor: 5.103

7.  Human metapneumovirus: enhanced pulmonary disease in cotton rats immunized with formalin-inactivated virus vaccine and challenged.

Authors:  Kevin C Yim; Rose P Cragin; Marina S Boukhvalova; Jorge C G Blanco; Marie-Eve Hamlin; Guy Boivin; David D Porter; Gregory A Prince
Journal:  Vaccine       Date:  2007-05-15       Impact factor: 3.641

8.  Respiratory syncytial virus fusion protein-induced toll-like receptor 4 (TLR4) signaling is inhibited by the TLR4 antagonists Rhodobacter sphaeroides lipopolysaccharide and eritoran (E5564) and requires direct interaction with MD-2.

Authors:  Prasad Rallabhandi; Rachel L Phillips; Marina S Boukhvalova; Lioubov M Pletneva; Kari Ann Shirey; Theresa L Gioannini; Jerrold P Weiss; Jesse C Chow; Lynn D Hawkins; Stefanie N Vogel; Jorge C G Blanco
Journal:  MBio       Date:  2012-08-07       Impact factor: 7.867

9.  Active immunoprophylaxis with a synthetic DNA-encoded monoclonal anti-respiratory syncytial virus scFv-Fc fusion protein confers protection against infection and durable activity.

Authors:  Katherine Schultheis; Holly M Pugh; Janet Oh; Jacklyn Nguyen; Bryan Yung; Charles Reed; Neil Cooch; Jing Chen; Jian Yan; Kar Muthumani; Laurent M Humeau; David B Weiner; Kate E Broderick; Trevor R F Smith
Journal:  Hum Vaccin Immunother       Date:  2020-06-16       Impact factor: 3.452
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.